PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

被引：8

作者：

Berges, Alienor ^{[1
]}

Cheung, S. Y. Amy ^{[1
]}

Pierce, Andrew J. ^{[2
]}

Dean, Emma ^{[3
]}

Felicetti, Brunella ^{[3
]}

Standifer, Nathan ^{[4
]}

Smith, Simon ^{[3
]}

Yates, James ^{[5
]}

Lau, Alan ^{[6
]}

Stephens, Christine ^{[3
]}

Krebs, Matthew ^{[7
,8
]}

Harrington, Kevin ^{[9
]}

Hollingsworth, Simon J. ^{[3
]}

机构：

[1] AstraZeneca, IMED Biotech Unit, Early Clin Dev, Quantitat Clin Pharmacol, Cambridge, England

[2] AstraZeneca, IMED Biotech Unit, Translat Sci, Oncol, Cambridge, England

[3] AstraZeneca, IMED Biotech Unit, Oncol, Cambridge, England

[4] MedImmune, Mountain View, CA USA

[5] AstraZeneca, IMED Biotech Unit, Oncol, DMPK, Cambridge, England

[6] AstraZeneca, IMED Biotech Unit, Oncol, Biosci, Cambridge, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Univ Manchester, Manchester, Lancs, England

[9] Royal Marsden NHS Fdn Trust, London, England

来源：

关键词：

D O I：

10.1158/1538-7445.AM2018-CT118

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT118

引用

页数：2